Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (134)	7/15/1998 6:43:00 AM
From: virgil vancleave	Read Replies (1) \| Respond to of 328

the best thing i like about anik is that it is still relatively unheard of and doesn't get much of aq following on wall street's radar screen. just look at the volume: it is still fairly low but has picked up. i am in at 12.875 and want some more. company is growing, has a low price to sales ratio (relative to other drug companies), no debt, has a nice cash balance and is recently profitable making it self sufficient. excellent ffor a med tech company. also like the fact that they recently moved to the nasdaq, which in my opinion is another plus. oh yea, has low float with low overall shares outstanding and management likes their own company. in march, 6 insiders bought shares according to yhoo. hope this helps. good luck